相互作用
Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin
重症度: 重大
Elvitegravir / cobicistat / emtricitabine / tenofovir df and Liposomal doxorubicin: major interaction.
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
概要
Cobicistat inhibits CYP3A4, CYP2D6 and P-glycoprotein, and may increase exposure to doxorubicin released from the liposome. This could worsen myelosuppression, mucositis, hand-foot syndrome and cardiotoxicity.
この相互作用をわかりやすく説明すると
Elvitegravir / cobicistat / emtricitabine / tenofovir df and Liposomal doxorubicin can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
なぜ起こるのか
Cobicistat inhibits CYP3A4, CYP2D6 and P-glycoprotein, reducing clearance of doxorubicin.
対処法
Prefer an unboosted antiretroviral regimen during therapy. If combined, monitor blood counts, mucocutaneous toxicity and cardiac function, and reduce the doxorubicin dose if toxicity appears.
薬剤師に尋ねること
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Elvitegravir / cobicistat / emtricitabine / tenofovir dfとLiposomal doxorubicinの臨床対応の詳細なアドバイス、追加の注記、エビデンスの詳細、処方全体を対象とした相互作用チェッカーを利用できます。
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
WebでPro+を14日間無料でお試し。カード登録不要。
Liposomal doxorubicinのその他の相互作用
よくある質問
Can I take Elvitegravir / cobicistat / emtricitabine / tenofovir df with Liposomal doxorubicin?
MediHelp rates the interaction as major. Elvitegravir / cobicistat / emtricitabine / tenofovir df and Liposomal doxorubicin can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Cobicistat inhibits CYP3A4, CYP2D6 and P-glycoprotein, and may increase exposure to doxorubicin released from the liposome. This could worsen myelosuppression, mucositis, hand-foot syndrome and cardiotoxicity.
How serious is the interaction between Elvitegravir / cobicistat / emtricitabine / tenofovir df and Liposomal doxorubicin?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Prefer an unboosted antiretroviral regimen during therapy. If combined, monitor blood counts, mucocutaneous toxicity and cardiac function, and reduce the doxorubicin dose if toxicity appears.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
